



**Biocon Limited**  
20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

BIO/SECL/SG/2024-25/179

February 18, 2025

To The Manager, <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 <b>Scrip Code - 532523</b>	To The Manager, <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 <b>Scrip Symbol - Biocon</b>
--	---

Dear Sir/Madam,

**Subject: Notification to Stock Exchanges**

Please find enclosed the company statement titled “**European Commission Approves Biocon Biologics’ Ustekinumab Biosimilar**”.

The above information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

\_\_\_\_\_  
**Mayank Verma**  
**Company Secretary & Compliance Officer**  
**Membership No: ACS 18776**

Encl: as above

## NOTIFICATION TO STOCK EXCHANGE

### COMPANY STATEMENT

# European Commission Approves Biocon Biologics' Ustekinumab Biosimilar

***Bengaluru, Karnataka, India, February 18, 2025***

**Biocon Biologics Ltd (BBL)**, a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the European Commission (EC) granted marketing authorisation in the European Union (EU) for YESINTEK<sup>®</sup>, a biosimilar of Ustekinumab.

YESINTEK<sup>®</sup>, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease. Clinical data from the trial program showed that Ustekinumab biosimilar has comparable safety and efficacy to the originator product.

The marketing authorisation approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued on December 14, 2024.

*– Company Spokesperson*

*YESINTEK is a registered trademark of Biocon Biologics Limited.*

*All other trademarks, registered or unregistered, are the property of their respective owners.*

*For more information: [seema.ahuja@biocon.com](mailto:seema.ahuja@biocon.com)*